From Yahoo Finance: 2025-05-21 06:37:00

BioNTech secures £1bn investment from UK government for R&D activities, with a grant of up to £129m. Partnership focuses on oncology, regenerative medicine, and infectious disease vaccines. Plans for two new R&D centres in Cambridge and London, including an AI hub. Aim to develop cancer immunotherapies and treatments by 2030.

BioNTech CEO Uğur Şahin highlights strategic partnership with UK government to expand access to cancer therapies. Accelerating R&D efforts to translate science into patient survival. UK’s MHRA authorizes Pfizer-BioNTech’s adapted vaccine for JN.1 Covid-19 subvariant. Commitment to advancing medical research with AI technology.

Pharmaceutical Technology reports BioNTech’s £1.34bn investment in UK R&D. Partnership aims to enhance research in oncology, regenerative medicine, and infectious disease vaccines. BioNTech plans to establish two new R&D centers in Cambridge and London, focusing on AI-driven medical research. MHRA approves Pfizer-BioNTech vaccine for new Covid-19 subvariant.



Read more at Yahoo Finance: BioNTech to invest up to $1.34bn in UK R&D